NEW YORK, May 29 – Molecular Staging of New Haven, Conn., announced Tuesday a handful of executive-level appointments, several of whom came from the leading companies in the genomics sector.
Michael Egholm, previously group leader for Applied Biosystems’ peptide nucleic acids core, has joined Molecular Staging as vice president of research; F. Scott Reding, previously chief financial officer for Zonagen, was named as Molecular Staging’s CFO; Peter Fuller, who was previously senior vice president of business development at CuraGen, has been appointed to the same position at Molecular Staging; Steve Piccoli, previously, COO of Diagnostic Oncology CRO, has joined as vice president of diagnostics; and Jennifer Joiner, previously vice president of commercial operations for Bayer Diagnostics’ laboratory testing segment, has been named vice president of marketing and strategic planning.
“These appointments represent an important milestone in the development of our organization as we move to expand commercialization activities with our technologies," Torben Christensen, Molecular Staging’s CEO, said in a statement.
Molecular Staging is developing a portfolio of technologies for the detection and measurement of proteins and nucleic acids. MSI's core technology is Rolling Circle Amplification Technology, a proprietary amplification process that has been exclusively licensed by Motorola for use in its diagnostic nucleic acid bioarrays.
Molecular Staging’s Rolling Circle Amplification Technology is an isothermal amplification process for detecting and measuring protein, DNA, and RNA. The technology is seen as useful in cutting costs and increasing throughput by eliminating the need for allele-specific amplification of DNA samples.